The approval for the three abbreviated new drug applications (ANDAs) broadens Accentia’s pain product portfolio, especially for chronic pain indications. Teamm Pharmaceuticals, Accentia’s wholly owned specialty pharmaceutical subsidiary, holds the exclusive US license for the marketing and sale of the three new formulations.
“Our sales force has been very effective in establishing our presence in the pain market with our Xodol brand for the treatment of moderate to moderately severe pain,” said Gary Cantrell, Teamm Pharmaceuticals executive vice president of sales and marketing. “The addition of these three new combination narcotic and analgesic products increases our comprehensive pain product portfolio to six, positioning the company to more effectively compete in an even larger segment of the chronic pain market.”
Each year, in the US alone, 45 million pain product prescriptions are written for the treatment of pain, ranging from mild and acute to severe, debilitating and chronic.